Details for Patent: 8,765,167
✉ Email this page to a colleague
Which drugs does patent 8,765,167 protect, and when does it expire?
Patent 8,765,167 protects EXSERVAN, SYMPAZAN, and KYNMOBI, and is included in three NDAs.
This patent has one hundred and sixty-one patent family members in eighteen countries.
Summary for Patent: 8,765,167
| Title: | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| Abstract: | The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent. |
| Inventor(s): | Myers; Garry L. (Kingsport, TN), Sanghvi; Pradeep (Schererville, IN), Verrall; Andrew Philip (Crown Point, IN), Francis; Vimala (Fremont, CA), Moss; Laura (Schererville, IN) |
| Assignee: | MonoSol Rx, LLC (Portage, IN) |
| Application Number: | 11/517,982 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,765,167 |
|
Patent Claim Types: see list of patent claims | Compound; Process; Delivery; |
Drugs Protected by US Patent 8,765,167
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive | EXSERVAN | riluzole | FILM;ORAL | 212640-001 | Nov 22, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,765,167
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 077803 | ⤷ Try a Trial | |||
| Austria | 536868 | ⤷ Try a Trial | |||
| Austria | 536869 | ⤷ Try a Trial | |||
| Austria | 553746 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
